A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia

Yu Hung Wang; Chi Yuan Yao; Chien Chin Lin; Kristian Gurashi; Fabio M.R. Amaral; Hasse Bossenbroek; Andres Jerez; Tim C.P. Somervaille; Moritz Binder; Mrinal M. Patnaik; Hsin An Hou; Wen Chien Chou; Kiran Batta; Daniel H. Wiseman; Hwei Fang Tien

doi:10.1111/bjh.18681

A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia

Yu Hung Wang, Chi Yuan Yao, Chien Chin Lin, Kristian Gurashi, Fabio M.R. Amaral, Hasse Bossenbroek, Andres Jerez, Tim C.P. Somervaille, Moritz Binder, Mrinal M. Patnaik, Hsin An Hou, Wen Chien Chou, Kiran Batta, Daniel H. Wiseman, Hwei Fang Tien

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

Leukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17-gene LSC score, LSC-17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three-gene expression signature (LSC-3, derived from the LSC-17 score) as an independent and robust prognostic factor for leukaemia-free and overall survival in CMML. We propose that LSC-3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.

Original language	English (US)
Pages (from-to)	302-307
Number of pages	6
Journal	British journal of haematology
Volume	201
Issue number	2
DOIs	https://doi.org/10.1111/bjh.18681
State	Published - Apr 2023

Keywords

chronic myelomonocytic leukaemia
leukaemia stem cell
prognostic scoring system

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.18681

Cite this

Wang, Y. H., Yao, C. Y., Lin, C. C., Gurashi, K., Amaral, F. M. R., Bossenbroek, H., Jerez, A., Somervaille, T. C. P., Binder, M., Patnaik, M. M., Hou, H. A., Chou, W. C., Batta, K., Wiseman, D. H., & Tien, H. F. (2023). A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia. British journal of haematology, 201(2), 302-307. https://doi.org/10.1111/bjh.18681

Wang, YH, Yao, CY, Lin, CC, Gurashi, K, Amaral, FMR, Bossenbroek, H, Jerez, A, Somervaille, TCP, Binder, M, Patnaik, MM, Hou, HA, Chou, WC, Batta, K, Wiseman, DH & Tien, HF 2023, 'A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia', British journal of haematology, vol. 201, no. 2, pp. 302-307. https://doi.org/10.1111/bjh.18681

@article{6c5f1bc43fb949308ed6c952cf837842,

title = "A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia",

abstract = "Leukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17-gene LSC score, LSC-17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three-gene expression signature (LSC-3, derived from the LSC-17 score) as an independent and robust prognostic factor for leukaemia-free and overall survival in CMML. We propose that LSC-3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.",

keywords = "chronic myelomonocytic leukaemia, leukaemia stem cell, prognostic scoring system",

author = "Wang, {Yu Hung} and Yao, {Chi Yuan} and Lin, {Chien Chin} and Kristian Gurashi and Amaral, {Fabio M.R.} and Hasse Bossenbroek and Andres Jerez and Somervaille, {Tim C.P.} and Moritz Binder and Patnaik, {Mrinal M.} and Hou, {Hsin An} and Chou, {Wen Chien} and Kiran Batta and Wiseman, {Daniel H.} and Tien, {Hwei Fang}",

note = "Publisher Copyright: {\textcopyright} 2023 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2023",

month = apr,

doi = "10.1111/bjh.18681",

language = "English (US)",

volume = "201",

pages = "302--307",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia

AU - Wang, Yu Hung

AU - Yao, Chi Yuan

AU - Lin, Chien Chin

AU - Gurashi, Kristian

AU - Amaral, Fabio M.R.

AU - Bossenbroek, Hasse

AU - Jerez, Andres

AU - Somervaille, Tim C.P.

AU - Binder, Moritz

AU - Patnaik, Mrinal M.

AU - Hou, Hsin An

AU - Chou, Wen Chien

AU - Batta, Kiran

AU - Wiseman, Daniel H.

AU - Tien, Hwei Fang

PY - 2023/4

Y1 - 2023/4

N2 - Leukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17-gene LSC score, LSC-17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three-gene expression signature (LSC-3, derived from the LSC-17 score) as an independent and robust prognostic factor for leukaemia-free and overall survival in CMML. We propose that LSC-3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.

AB - Leukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17-gene LSC score, LSC-17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three-gene expression signature (LSC-3, derived from the LSC-17 score) as an independent and robust prognostic factor for leukaemia-free and overall survival in CMML. We propose that LSC-3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.

KW - chronic myelomonocytic leukaemia

KW - leukaemia stem cell

KW - prognostic scoring system

UR - http://www.scopus.com/inward/record.url?scp=85147495122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147495122&partnerID=8YFLogxK

U2 - 10.1111/bjh.18681

DO - 10.1111/bjh.18681

M3 - Article

C2 - 36746431

AN - SCOPUS:85147495122

SN - 0007-1048

VL - 201

SP - 302

EP - 307

JO - British journal of haematology

JF - British journal of haematology

IS - 2

ER -

A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this